Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan, Dabrafenib, Trametinib and Anti-EGFR in BRAF-Mutated Colorectal Cancer
NCT06967155Phase 2Active, not recruiting
- Sponsor
- N.N. Blokhin Russian Cancer Research Center
- Start
- Mar 2025
- Primary completion
- Nov 2027
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dabrafenib + trametinib, trametinib, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colorectal cancer (CRC), sponsored by N.N. Blokhin Russian Cancer Research Center. Started Mar 2025; status: active, not recruiting.
02
Drugs
dabrafenib + trametinibtrametinibirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06967155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06967155.